Timing of Puberty, Pubertal Growth, and Adult Height in Short Children Born Small for Gestational Age Treated With Growth Hormone
Research output: Contribution to journal › Journal article › Research › peer-review
Context: Growth hormone (GH) is used to treat short children born small for gestational age (SGA); however, the effects of treatment on pubertal timing and adult height are rarely studied. Objective: To evaluate adult height and peak height velocity in short GH-treated SGA children. Methods: Prospective longitudinal multicenter study. Participants were short children born SGA treated with GH therapy (n = 102). Adult height was reported in 47 children. A reference cohort of Danish children was used. Main outcome measures were adult height, peak height velocity, age at peak height, and pubertal onset. Pubertal onset was converted to SD score (SDS) using Danish reference data. Results: Gain in height SDS from start of treatment until adult height was significant in both girls (0.94 [0.75; 1.53] SDS, P = .02) and boys (1.57 [1.13; 2.15] SDS, P < .001). No difference in adult height between GH dosage groups was observed. Peak height velocity was lower than a reference cohort for girls (6.5 [5.9; 7.6] cm/year vs 7.9 [7.4; 8.5] cm/year, P < .001) and boys (9.5 [8.4; 10.7] cm/year vs 10.1 [9.7; 10.7] cm/year, P = .002), but no difference in age at peak height velocity was seen. Puberty onset was earlier in SGA boys than a reference cohort (1.06 [-0.03; 1.96] SDS vs 0 SDS, P = .002) but not in girls (0.38 [-0.19; 1.05] SDS vs 0 SDS, P = .18). Conclusion: GH treatment improved adult height. Peak height velocity was reduced, but age at peak height velocity did not differ compared with the reference cohort. SGA boys had an earlier pubertal onset compared with the reference cohort.
Original language | English |
---|---|
Journal | Journal of Clinical Endocrinology and Metabolism |
Volume | 107 |
Issue number | 8 |
Pages (from-to) | 2286-2295 |
Number of pages | 10 |
ISSN | 0021-972X |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Funding Information:
A.J. has received an unrestricted research grant from Novo Nordisk (North European Study on GH treatment in short SGA children), and lecture fees from Novo Nordisk, Ferring, Ipsen, Sandoz and Pfizer International. R.B.J. has received lecture fees from Novo Nordisk. Prof JMW Kirk has a paid consultancy with Novo Nordisk. L.L.R. is a full-time employee of Novo Nordisk. The other authors have nothing to declare.
Funding Information:
This study was financed by an unrestricted research grant from Novo Nordisk. E.N.U. was funded by the Candy Foundation (nos. 2017-224, 2020-344).
Publisher Copyright:
© 2022 Endocrine Society. All rights reserved.
- adult height, GH treatment, peak height velocity, puberty, SGA
Research areas
ID: 320868419